Adverum Biotechnologies, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
BML Investment Partners and Braden M. Leonard have fully divested their beneficial ownership in Adverum Biotechnologies, Inc. common stock.
BML Investment Partners and Braden M. Leonard have reduced their beneficial ownership in Adverum Biotechnologies, Inc. to an aggregate of 9.7% after selling over 1 million shares.
BML Investment Partners and Braden M. Leonard, holding 15.6% of Adverum Biotechnologies, express deep disappointment with the Eli Lilly merger terms and the board's handling of the sale process.
BML Investment Partners, L.P. and Braden M. Leonard have disclosed a combined beneficial ownership of 15.6% in Adverum Biotechnologies, Inc., acquired for investment purposes with potential for future strategic discussions.